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Detection & Identification of Infectious Agents (DIIA) Innovation 
Platform: Health Econometrics 
 
Area: Sexually Transmitted Infections (STIs) 
 
 
 
Introduction: 
 
A number of clinical/disease areas have been prioritised by the Technology Strategy Board (TSB) 
and Department of Health (DH) for the DIIA Innovation Platform.  To support commissioning of 
technology development for detection of sexually transmitted infections (STIs) in humans, a 
scoping review has been undertaken to help identify the specific requirements for new diagnostic 
test development and likely economic payback for point of care (POC) tests for STIs in the UK. 
 
This report presents economic analysis findings for the following two STIs: 
 Genital Chlamydia trachomatis (Chlamydia) 
 Neisseria gonorrhoeae (N gonorrhoeae) 
 
Framework: 
 
An evaluative framework was developed within which any new POC diagnostic technology could 
be considered.  The final framework was agreed with the TSB and Department of Health.  The 
study adopted a pre-defined methodology.  The health economics team undertook literature 
reviews, evidence synthesis, and economic modelling/early-health technology assessment 
(HTA) of POC tests for each infection type.  Independently, a scientific team examined the 
characteristics of existing laboratory tests for these infections and outlined the performance 
parameters required for an ‘ideal’ POC test.  These ideal test parameters were then used in 
economic modelling, along with evidence from the literature review. 
 
The health economic scoping study was based on two main elements: (i) UK burden of 
illness: estimation of national costs associated with each infection (including mortality, 
morbidity and treatment costs) and the cost of diagnosis and screening using current tests; 
(ii) UK economic model: POC testing scenarios were mapped against existing tests to 
estimate any clinical or cost consequences (on positives detected, false negatives/false 
positives reported, infections transmitted, and healthcare and mortality costs) and the likely 
impact of widespread POC test introduction was estimated.  The main analysis focused on 
estimating incremental direct costs on moving from current tests to a new POC test.  For 
different scenarios, the model estimated the total cost of resource use and the number of 
infections detected.  Historical costs extracted from the literature were inflated to 2007/08 
prices.  A one-day workshop was held in which preliminary findings from the model were 
presented to national experts.  The model was then further refined based on expert opinion 
and additional information provided by group members.  The model excluded longer term 
impact on antibiotic resistance which is difficult to quantify robustly in monetary terms. 
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1.1  Introduction 
 
Sexually transmitted infections (STIs) are a major global cause of acute illness, infertility, 
long-term disability and death, presenting significant medical, social, and economic 
problems.[1]  An estimated 333 million new curable STIs occur every year among men and women 
aged 15 to 49 years worldwide.[2]  The World Health Organization estimates that this figure 
includes 150 million Chlamydia trachomatis and Neisseria gonorrhoeae infections, the majority of 
which occur in developing countries.[3]  If untreated, both these STIs can cause serious long term 
complications, especially those affecting the reproductive health of women. 
 
Both infections also facilitate HIV transmission, a fact which is particularly important in the 
developing world.[4]  Of the estimated 40,000 to 80,000 new HIV infections that occur each year, 
5,052 or more could result from the facilitating effects of syphilis, chlamydia, gonorrhoea, and 
genital herpes on HIV transmission.[5]  In urban Africa, it has been estimated that for each female 
N gonorrhoeae case prevented, 1.0 DHLY (discounted healthy life years) would be saved; and 1.3 
DHLY for each Chlamydia case prevented.[6] 
 
A syndromic approach to management of STIs has served as a major step towards improved 
management in developing countries.[7, 8]  A recent study in Taiwan reports that syndromic 
management is cost-effective for male patients attending STD clinics with symptoms (urethral 
discharge symptoms and genital ulcers).[9]  However, this approach does not address the issue 
of asymptomatic or subclinical STIs.[10, 11]  In the western world, case management is therefore 
usually based on laboratory-confirmed diagnosis.[12]  The economic analysis below therefore 
excludes any consideration of syndromic management. 
 
 
1.2  Economic burden of disease 
 
1.2.1 Genital Chlamydia trachomatis (Chlamydia): Economic burden of disease 
 
Chlamydia mortality: 
The peak age group for chlamydia infection is 16–19 years in women and 20–24 years in men.[13]  
However, there is a negligible longer-term risk of death, mainly associated with ectopic 
pregnancies and with increased HIV transmission.  Therefore, for the purposes of this 
economic analysis, the mortality cost associated with chlamydia is assumed to be zero. 
 
Chlamydia morbidity: 
Chlamydial genital tract infections can cause a range of clinical disorder.[14]  Since chlamydia is 
asymptomatic in 70-90% of cases many infections remain untreated.[15]  Once diagnosed, the 
infection is easy to treat.  Women sustain the most severe consequences of untreated infection, 
including pelvic inflammatory disease (PID), chronic pelvic pain, ectopic pregnancy, and tubal 
infertility.  If undiagnosed, chlamydia leads to PID in 10-40% of cases, with infertility resulting in 
up to 20% of these women, and the risk of ectopic pregnancy greatly increases in others, although 
some researchers suggest these figures may overestimate the effect.[16]  Associated disorders are 
less serious in men, principally limited to epididymitis.[17] 
 
The national morbidity burden associated with undiagnosed chlamydia depends on the number of 
such cases in any one year.  The prevalence of undiagnosed chlamydia is similar in men and 
women.[18]  In 2007, the national screening programme in England screened 270,729 people 
(target group aged under 25 years); the positive rate was 9.3% (9.5% in women and 8.4% in men) 
identifying a total of 24,236 cases.[19]  A further 121,986 UK diagnoses of genital Chlamydia 
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infections were made in GUM clinics (79,557 in people aged under 25 years).  Thus, a total of 
~146,300 chlamydia cases were diagnosed in 2007 in the UK. 
 
The number of cases undiagnosed will depend on the underlying prevalence in the whole 
population.  The British National Survey of Sexual Attitudes and Lifestyles 2000 found chlamydia 
in 2.2% of men and 1.5% of women aged 16–44 years.[20]  Similar figures of 2.3% in men and 
2.9% in women aged 15–40 year olds are reported in an Amsterdam study which sampled 4,560 
patients from general practice lists.[21]  A recent UK study found a higher prevalence of ~6% 
(5.0% in men and 7.2% in women) in 528 patients tested from GP practice lists.[22]  A figure of 5% 
has been used for the UK in another study.[23]  Applying a rate of ~6% to the population in 
England aged 16-25 (~5.62 million people) indicates a total figure of ~340,000 infections.  The 
number diagnosed in this age group through screening in 2007 is only 43% of this figure.  Thus, 
any estimate of national morbidity costs based on diagnosed cases alone is likely to undervalue the 
actual economic burden of chlamydia infection. 
 
In terms of health related quality of life (HRQoL), the subclinical state of PID is reported to lead to 
no reduction (health utility = 1).  Although there is a significant impact on women’s health status 
due to ectopic pregnancy (0.58) and due to clinical PID (0.65), both are of a limited duration (2-6 
weeks) so are also usually set to zero.[14]  Similarly, although chronic pelvic pain (health state 0.6) 
can be of much longer duration, this is difficult to quantify accurately.  For the purposes of the 
present economic analysis, the latter was also set at zero. 
 
More problematic is the longer-term impact of infertility on women’s HRQoL.  In the US, there are 
roughly 1 million cases of PID each year leading to approximately 150,000 to 200,000 women 
becoming involuntarily infertile as a result of bilateral obstruction of the fallopian tubes.  At least a 
quarter of such cases in the US can be attributed to chlamydial infection.[24]  In the UK, the figure 
is thought to be probably nearer 50%.[25]  Of women with infertility, only those with a pregnancy 
wish, who undergo in vitro fertilisation (IVF) treatment or have unsuccessfully undergone IVF 
treatment, are assumed to experience a decreased utility.[26] 
 
Finally, if the infection is not treated it may be passed on to the newborn.[17]  From 30% to 40% of 
infants born to mothers with untreated chlamydial infection during pregnancy will develop neonatal 
conjunctivitis, and up to 22% will develop pneumonia.[27, 28]  
 
Because the impact of the various clinical consequences above of chlamydia infection could not be 
quantified in terms of HRQoL, it is not possible to estimate the number of QALYs lost. 
 
All the sequelae above were instead built into the economic model in terms of their likelihood 
and the cost of treatment (see section 1.5).  The model excluded any estimate of QALYs lost or of 
psychological morbidity due to infertility, though this may be considerable. 
 
Costs to society: 
In the UK, the annual cost to the tax payer of investigating and treating chlamydia and its 
complications is estimated at over £100 million.[29] 
 
1.2.2 Neisseria gonorrhoeae: Economic burden of disease 
 
N gonorrhoeae mortality: 
There is similarly a negligible risk of death associated with N gonorrhoeae infections.  The 
number of infections is also significantly lower than for chlamydia.  Therefore, once again, the 
mortality cost can be assumed to be zero. 
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N gonorrhoeae morbidity: 
As with chlamydia, gonorrhoea can cause a range of clinical disorder, primarily in women.[30]    
However, there is still considerable uncertainty about the natural history of acute gonococcal 
infection.[26]  Infection is frequently asymptomatic in women, which can create a large pool of 
undetected infections.  Women with untreated cases of gonorrhoea have a 16% probability of 
developing PID [31-33]; reported figures range from 10% to 40%.[30]  PID once again leads to 
various disorders, including chronic pelvic pain, ectopic pregnancy, and tubal infertility.  For men, 
associated disorders are less serious; they are largely limited to acute urethritis and 
epididymitis.[30]  
 
If the infection is not treated in a pregnant woman it may be passed on to the newborn.  Complications 
of untreated gonococcal infection in the neonate include conjunctivitis, ophthalmia, arthritis, and 
adverse pregnancy outcomes.[34] 
 
In 2007, 18,710 cases of uncomplicated N gonorrhoeae were identified in UK GUM clinics.[19]  
The prevalence of gonorrhoea is far lower than for chlamydia, with figures of 1% (vs 6% for 
chlamydia) reported in US populations [35]; 1% prevalence has been used in economic modelling 
[33]; and figures of 0.1–2.8% are reported for asymptomatic young women.[36]  Applying a 
conservative rate of 1% to the population in the UK aged 16-25 years (~6.6 million people) would 
indicate a total figure of 66,000 N gonorrhoeae infections in this age group.  The total number 
diagnosed in 2007 is 28% of this figure, indicative of a larger proportion of undiagnosed infections 
than for chlamydia.  If this is the case, a national morbidity cost based on diagnosed cases is likely 
to underestimate the full economic burden of this disease. 
 
As with chlamydia, the impact of the various clinical consequences of N gonorrhoeae infections 
on HRQoL is not recorded.  Therefore, it is not possible to estimate the number of QALYs lost.  
However, all these sequelae are built into the economic cost model (see section 1.5). 
 
 
1.3  Cost of current treatment and control 
 
1.3.1 Chlamydia: Cost of current treatment and control 
 
Chlamydia treatment: 
Once identified, treatment will encompass relief of symptoms, rapid eradication of Chlamydia 
trachomatis, and contacting sexual partners.  Drug treatment is relatively inexpensive with a one-
dose antibiotic treatment available, estimated at a total cost per case of £61-£65 in the UK.[17]  
Based on 146,300 detected chlamydia infections, annual drug costs (2007/08) are estimated to be 
£8.92 - £9.51 million per annum. (£1.48 - £1.58 million for cases identified through screening) 
 
Management of chlamydia also requires that sexual health education is provided to promote risk 
reduction in future sexual behaviour. 
 
Chlamydia screening (national programme): 
Screening of asymptomatic female populations for chlamydia has been advocated by several 
authors.[37-41]  Various studies have examined the cost-effectiveness of active and opportunistic 
screening in different populations [32, 42, 43]  Research has demonstrated that several years after 
the introduction of a screening programme, there are reduced hospitalisation rates for ectopic 
pregnancy [44] and for PID [40] as well as a decrease in diagnosed chlamydia infections.[37, 40]  The 
evidence indicates that age-selective screening is cost-effective when compared with no 
screening.[45]  Most studies assess screening in a female population.  A focus on screening women 
only assumes that partners will be picked up by partner notification programmes.[45]  However, 
these programmes have been shown to reach only 50% to 60% of partners.[46]  Also research 
indicates that asymptomatic chlamydia is as common in men as women.[47]  Furthermore, although 
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opportunistic screening of women in Sweden was initially associated with a reduced prevalence, 
subsequent increases highlighted the need to screen men as well.[48] 
 
Opportunistic screening has been piloted in the UK [49, 50] and the Netherlands [51], 
demonstrating that this approach is feasible and acceptable.  In 2003, the House of Commons 
Health Committee report on sexual health recommended phased introduction of a national 
programme of opportunistic screening in men and women in England.[52]  Screening was to be 
offered to everyone under 25 (men and women) attending selected health service settings, 
including family planning clinics, GUM clinics (individuals not normally receiving a sexual health 
screen), antenatal/ gynaecology clinics, military facilities, university medical practices, and 
general practices.  The introduction of more sensitive nucleic acid amplification tests (NAATs) to 
replace lower sensitivity enzyme immunoassays was also recommended.  The Department of Health 
pump primed the implementation of the programme, providing up to £150,000 to each locality in 
England for the first year, and full funding for years 2 and 3, after which all local programme costs 
were to be picked up by PCTs.  Recently, Adams et al have cast doubt on the cost-effectiveness of 
opportunistic chlamydia screening as implemented in the English National Chlamydia Screening 
Programme.[17]
 
 
 
Various costs have been reported for chlamydia screening.  The average cost per screening offer has 
been estimated at approximately £15 for negative screens and £38 for positives.[53]  In 2007, 
270,729 people were screened in England.  Based on these figures, an annual screening cost of 
£4.64 million can be calculated for 2007.  Other researchers have estimated a total cost per 
screening invitation of £20.37, (including NHS costs of £13.55 and average patient
 
costs of £6.82); 
administrative
 
costs accounted for 50% of the overall cost.[54]  The same authors report that the 
cost of proactive chlamydia screening in the NHS is comparable
 
to that of opportunistic screening.  
In another study, EIA testing for chlamydia is reported to cost £2.88 per sample.[55]  For large 
scale testing of pregnant women for Chlamydia trachomatis, the use of pooled urine samples has 
been reported to reduce unit costs to 56% in the Netherlands without reducing performance.[56] 
 
Chlamydia diagnosis (GUM clinics): 
Some patients continue to present at GUM clinics for a diagnosis (i.e. not for sexual health 
screens).  In 2007, a further 121,986 chlamydia cases were diagnosed in the UK through this route, 
the majority (79,557) in those aged 16-24.  The reported prevalence in people presenting themselves 
for testing is 17.3%.[23]  Applying this prevalence rate produces a total figure of 705,121 patients 
tested.  This equates to an annual diagnostic cost of £12.41 million (once again assuming £15 for a 
negative test and £38 for a positive). 
 
Based on the calculations above, the annual cost for chlamydia testing in the UK is currently 
£17.05 million for an estimated 975,800 people being tested (28% through the English national 
screening programme). 
 
1.3.2 N gonorrhoeae: Cost of current treatment and control 
 
N gonorrhoeae treatment: 
The emergence of ciprofloxacin-resistant N gonorrhoeae strains in the USA has made treatment 
with cephalosporins such as ceftriaxone necessary in some cases.[57]  In the UK, although it can be 
anticipated that resistance to penicillins, tetracyclines, and quinolones will all exceed 5%; actual 
treatment failures are rare because gonorrhoea treatment is frequently combined with a tetracycline 
or macrolide to manage possible co-incidental chlamydial infection.[58]  Drug treatment for 
gonorrhoea involves a relatively inexpensive single dose estimated at £2.55 per person (drug cost 
only). [59]  It has been suggested that routine dual therapy (treating for chlamydia without testing 
for this infection) could be cost-effective for populations in which chlamydial infection accompanies 
20%–40% of gonococcal infections.[60].  This is because the cost of therapy for chlamydia is less 
than the cost of testing. 
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Based on 18,710 gonorrhoea cases in 2007 and a treatment cost (drug only) of £2.55, annual drug 
costs are estimated to be £0.05 million per annum. 
 
N gonorrhoeae screening: 
In the USA, gonorrhoea screening is being implemented in several areas, although no 
structured guidelines are yet in place.  A recent study compared different screening strategies for 
gonorrhoea and concluded that no screening strategy was cost-saving.[30]  However, at a 3% 
prevalence of gonorrhoea the most cost-effective screening strategy was to test women < 25 years 
with specific risk factors (i.e. pregnant, drug use, new sexual partner <30 days).  Sensitivity analysis 
identified a threshold of 4.75% gonorrhoea prevalence above which this screening strategy would 
become cost-saving over not screening.  The authors therefore recommended screening for women 
<25 years with specific risks in populations with a gonorrhoea prevalence of ≥4.75%.  A cost-
effectiveness analysis examining gonorrhoea screening in emergency departments has also 
found that point-of-care testing is significantly more cost-effective than urine based diagnostics, 
primarily because it improves the proportion of infected women treated.[26]  Although selective 
screening seems to be cost-saving in high prevalence populations, such as emergency 
department patients, another analysis suggests that general population-based screening for 
gonorrhoea would not be cost-saving.[30] 
 
A number of cost-effectiveness analyses have examined combining chlamydia and gonorrhoea 
testing.[61-63]  In a study in an emergency department setting, screening women aged 18 to 31 
years for Chlamydia trachomatis and gonorrhoea was reported to be cost-saving over not 
screening if the chlamydia prevalence exceeds ~6%.[61]  Universal screening of women for 
chlamydia and gonorrhoea has also been found to be cost-saving in a detention setting.[64]  
However, a recent editorial has advised that gonorrhoea screening in women is not recommended 
unless chlamydia screening is already offered because chlamydia prevalence is higher than gonorrhoea 
in nearly all settings.[65]  
 
There is no national gonorrhoea screening programme in the UK, and no policy of combined 
screening for Chlamydia trachomatis and N gonorrhoeae. 
 
N gonorrhoeae diagnosis (GUM clinics): 
The 2004 updated British Association of Sexual Health and HIV (BASHH)/ National guidelines on 
gonorrhoea include reference to detection of N gonorrhoeae by nucleic acid amplification tests 
(NAATs). [66]  A NAAT testing cost of $US14 per test (2002 prices) is reported for urine and 
cervical specimens; this includes labour, consumables and equipment costs [26]  A similar figure 
has been estimated for antibody tests (ELISA) at ~€7.8-8.4 (2004 prices) [67].  A lower figure is 
reported for culture tests at US$5 (2001 prices). [33]. 
 
Other patient management costs, including contacting and treating sexual partners and providing 
sexual health education, will be similar to those for chlamydia.[53] 
 
18,710 gonorrhoea cases were diagnosed in GUM clinics in 2007, of which 50% (9,410) were in 
young people under 25 years old.  Assuming a prevalence of 20%, in patients presenting at GUM 
clinics for testing (similar to that observed for chlamydia) would indicate at total figure of ~93,550 
patients tested.  This represents an annual diagnostic cost of £1.83 million (once again assuming 
£15 for a negative test and £38 for a positive). 
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1.5  Estimating the economic benefits which new tests could provide 
 
1.5.1 Overview of economic analysis and model used 
 
Current testing scenarios (Table 1): 
Table 1 presents an overview of the UK status quo for Chlamydia trachomatis and N gonorrhoeae 
testing.  Comparative data are provided for the technical performance (sensitivity/specificity) of 
tests currently used; times to result; and the location of testing.  The numbers of patients being 
tested annually is also estimated.  For Chlamydia trachomatis population screening tests are 
distinguished from those identified by other means. 
 
The final two columns in Table 1 summarise the economic impact of each infection in the UK, as 
detailed in sections 1.2 and 1.3 above. 
 
New testing scenarios (Table 2): 
Table 2 presents the characteristics of an ‘ideal’ new test for detecting these infections. 
 
A costing model has been constructed in Excel to estimate the impact on national level costs of 
moving from the current status quo to implementation of one of the new tests.   We also 
modelled various future scenarios. 
 
The economic model: 
A cost model was constructed in Excel to estimate the costs of screening, diagnosis and treatment of 
chlamydia and gonorrhoea infections, and the development and treatment of complications in 
undiagnosed cases (i.e. PID, infertility, ectopic pregnancy etc).  In our analysis we focused on 
estimating incremental direct costs on moving from current tests to the proposed new test.  For 
different scenarios, the model estimated the total cost of resource use and the number of infections 
detected. 
 
Data in the model: 
The model parameters were based on the highest level of evidence available from our review of the 
literature.  An overview of the parameter values used is shown in Table 3a. 
 
Probabilities: 
For screened populations, our model used the prevalence rate of 9.3% for chlamydia in the national 
screening programme (higher than general population rates) [68] and 1.75% for gonorrhoea (based 
on incidence rate difference). 
 
For GUM clinics (diagnostic) we used the reported rate of 17.5% for Chlamydia and an assumed 
rate of 20% for gonorrhoea. 
 
Incidence rates used for the UK population were 800/100,000 for chlamydia [69] and 196/100 000 
for 20–24 year old men and 133/100 000 for 16–19 year old women in 2005 for gonorrhoea.[70] 
 
We hypothesised that false negatives (FN) would result in infection transmission as well as clinical 
complications.  Thus, better test sensitivity will decrease the number of FN cases and lead to 
savings due to fewer infections as well as the associated cost of medical conditions caused by 
undetected chlamydia and gonorrhoea. 
 
For chlamydia the infection transmission rate is reported at 40% (male-to-female, single exposure), 
and the female-to-male transmission rate has been estimated as 32%.  Other investigators report 
similar transmission rates for both sexes. [71]  For modelling we assumed a transmission rate of 0.4 
for male-to-female and female-to-male. 
Detection & Identification of Infectious Agents (DIIA) Innovation Platform 
Area C: Sexually Transmitted Infections (STIs) 8 June 2009 7  
 
For gonorrhoea the male-to-female transmission rate is 80% and the transmission rate from 
females to males is approximately 20%.[72]  For modelling we assumed 0.5 transmission rate as the 
average of those stated above. 
 
Currently there are more women screened for chlamydia than men.  The number of men aged under 
25 accessing screening has increased each year, from 7% in 2003/04 to 21.1% in 2006/07. [73].  For 
modelling purposes we used a figure of 21% to account for the older age groups undergoing 
diagnostic testing in GUM clinics.  For gonorrhoea, we assumed 25% of those tested are male. 
 
More than 60% of newborns who deliver through a chlamydia-infected cervix will acquire the 
infection.[71]  We used a figure of 60%. 
 
In people diagnosed with gonorrhoea, co-infection with chlamydia is reported in 10–40% cases in 
the USA and UK; in people diagnosed with chlamydia, co-infection with gonorrhoea is reported in 
20-40% overall.[70] 
 
Population tested: 
For Chlamydia trachomatis and N gonorrhoeae testing we estimated the economic benefit of 
replacing current tests with the new test in the current setting. 
 
We estimated the economic benefit if a new combined test were used to detect gonorrhoea and 
chlamydia in all samples tested.  We tested the sensitivity of the economic impact by varying the 
assumed testing throughput for chlamydia in the range 1 million – 5 million samples per annum, 
and for gonorrhoea in the range 100,000 – 1 million samples.  The lower figures approximate to 
the current situation for both infections.  For chlamydia, it was assumed that the additional 1-4 
million samples tested (above the current 1 million) would exhibit a similar prevalence of 
Chlamydia trachomatis as screened samples (9.3%). 
 
Costs: 
For each testing scenario, we estimated the number of cases of untreated infection and 
subsequent sequelae in women and men, episodes of transmission to sexual partners, 
congenital infections prevented, as well as prevention costs, as the outcomes considered in 
this economic analysis.  The sequelae and probabilities of outcomes from an untreated 
infection were derived from the literature and are shown in Table 3b.  Published reports 
show the probability of PID ranges from 10% to 40%.  We assumed a 25% probability of PID in 
our base case analysis for chlamydia, and 16% for gonorrhoea.[23, 33]  For long-term sequelae, 
we included the probabilities of ectopic pregnancy and tubal infertility; chronic pelvic pain was 
excluded in this simple model.  Additionally, we included the cost of transmission of 
infection to a male sexual partner, with subsequent epididymitis; urethritis costs are small 
and were excluded.  For women, we also included impact on neonatal outcomes. 
 
The cost of treatment of infection, PID, tubal infertility, and ectopic pregnancy were apportioned 
to untreated infections among women.  Treatment costs for men were similarly apportioned.  
Ectopic pregnancies and tubal infertility are expected to occur in the future, so their cost was 
discounted.  An amount was added to the basic drug cost of treatment for gonorrhoea to 
produce a total cost of £52. 
 
Indirect and intangible costs associated with PID, including lost time from school and work, pain, 
anxiety, and the profound sense of loss due to infertility, were not included in the analysis.  
Thus, the costs cited in Table 3b are an underestimate when one considers the subsequent 
physiological sequelae and psychological morbidity. 
 
Detection & Identification of Infectious Agents (DIIA) Innovation Platform 
Area C: Sexually Transmitted Infections (STIs) 8 June 2009 8  
The total predicted annual cost savings in Table 2 were derived from incidence of 
complications and their estimated cost.  Outcome of infection and associated costs were 
applied to the annual testing throughputs and cohorts of men and women described above. 
 
 
1.5.2 Economic conclusions 
 
Table 4 shows that, if the new Point of Care test replaces current EIA testing in the manner 
described (at no increase to unit test cost), there is a predicted cost saving based on improved test 
performance for chlamydia and gonorrhoeae tests. 
 
At current testing levels (Minimum scenario), the annual financial benefit predicted with the new 
test is a saving of £13.9 million (assuming no increase in unit test cost); £12.9 million for chlamydia 
and ~£1 million for gonorrhoeae.  Under this scenario, which most closely approximates the 
current status quo, moving to the new test would detect an additional 37,500 (35% increase) 
chlamydia infections and 1,600 (9% increase) gonorrhoea. 
 
The national saving at the higher throughput (Maximum scenario) is greater.  A predicted saving of 
£47.2 million per annum; more sizeable for chlamydia (annual savings of £41.8 million) and 
smaller for gonorrhoea (annual saving of £5.4 million).  In addition, 133,250 more chlamydia 
infections will be detected and 16,000 gonorrhoea. 
 
The economic benefits above are modelled based primarily on the change in test sensitivity and 
specificity.  Although the new test also offers a shorter turn-around time, we could not identify any 
data to enable us to model a decrease in time to result from 15 minutes to 5 minutes; we have 
therefore assumed that this would not produce a significant impact on treatment and final outcome 
costs. 
 
Emerging technologies: 
A chlamydia rapid test developed by the Diagnostics Development Unit at Cambridge University 
was recently reported in the BMJ.  Compared with PCR, the sensitivity and specificity were 83.5% 
and 98.9% respectively.[74]  Since this is not currently commercially available it was not included 
in current test figures for economic analysis. 
 
A chlamydia home testing kit, promising next-day results, is also being marketed direct to women 
by companies provided in Table 5.  Since our new test scenarios exclude self-testing, this 
possibility has not included in the present economic model.  Large scale self-testing might impact 
on the national chlamydia screening programme, decreasing the number of people currently 
accessing this.  But it is more likely not to impact on this group but to increase testing in other hard 
to reach groups who currently do not wish to make use of NHS services for this purpose. 
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TABLE 1:  Overview and summary of current tests for genital Chlamydia trachomatis and Neisseria gonorrhoeae 
 
Clinical 
context 
Current UK test 
context 
Current tests used Current test capability 
Current economic 
impact 
Number of 
UK 
patients 
tested 
annually 
Settings 
where tests 
undertaken 
Type of tests 
used 
Test 
process 
Type of 
specimen 
Time to 
perform 
test/result 
Sensitivity/ 
Specificity 
Annual 
Testing 
Cost 
 
Annual  
Burden of 
Disease
1
  
Chlamydia/ 
Gonorrhoeae 
N/A Laboratory 
Nucleic acid 
amplification 
test (NAAT) 
Predominant 
test used 
One step 
Urine, 
endocervical 
~ 3h ~95/98 N/A N/A 
Chlamydia 
Screening 
270,730 POC EIA One step Urine ~15 mins ~70/95
2
 
£4.64 
million 
Treatment: 
£1.48 - £1.58 
million 
 
Chlamydia 
Detection 
705,120 POC EIA One step Urine ~15 mins ~70/95 
£12.41 
million 
Treatment: 
£7.44 - £7.93 
million 
 
        
Total: 
£17.05 
million 
Total: £8.92-
£9.51 million 
        
GRAND TOTAL = £26.0 – 
£26.6 million 
Gonorrhoeae 
Detection 
93,550 POC EIA One step 
Endocervical, 
urine 
~15 mins ~87/~87 £1.83 million 
Treatment: 
£0.05 million 
 
        
GRAND TOTAL = £1.88 
million 
1
 Mortality costs assumed to be negligible. 
2  An assessment of a Chlamydia rapid test (currently not commercially available) developed by the Diagnostics Development Unit at Cambridge University was recently reported in the BMJ.  Compared 
with PCR, the reported sensitivity/ specificity of this test is 83.5/ 98.9 respectively.[74] 
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TABLE 2:  Predicted likely economic benefits of new test for Genital chlamydia trachomatis and Neisseria gonorrhoeae 
 
 
 
 
 
 
 
 
 
 
 
Main 
driver(s) for 
technology 
development 
 
New test 
UK role 
 
Target population/  
sub-population 
 Ideal new test requirement 
Predicted economics of 
new test  
 
 
 
 
Main driver for 
technology 
implementation 
 
Target 
population 
to be tested 
 
Number of 
UK patients 
 
Time 
to 
result 
 
Sensitivity
/ 
Specificity 
 
Setting 
for test 
 
 
Test  
process  
 
Break-
even 
Test Cost 
 
 
Annual  
Cost saving
1
 
[Additional 
cases 
detected] 
 
Genital 
chlamydial  
 
and 
 
gonorrhoeae 
 
infections 
 
Currently 
POC tests 
have a lower 
sens & spec 
than lab tests. 
Decrease 
time to result 
POC tests. 
Decrease in 
cost POC. 
Detection 
and 
screening 
Symptomatic 
patients/ 
contact 
tracing. UK 
screening 
programme 
high risk 
populations 
(i.e. women 
and men 
aged 16-24) 
 
1 million 
(Chlamydia) 
 
100,000 
(Gonorrhoeae) 
 
< 5 
mins 
 
95/95 
 
Point of 
care 
 
Urine 
 
£29.72 
 
 
 
£13.9 million 
[39,100] 
 
Cost saving and 
more cases 
detected 
 
1
  Base case assumes ~1 million people enter system for chlamydia testing (28% through the national screening programme); and 100,000 for gonorrhoeae testing. 
2
 Ratio of: [Current total spend on diagnosis (£18.8 m) + predicted savings due to improved test performance (£13.9 m)]/ Number of tests performed (1.1 million). 
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Aims for new diagnostic tests 
 Identify infected patients and intiate treatment 
 Use for screening of contacts to interupt transmission in non-symptomatic patients 
 Avoid unnecessary and inappropriate antimicrobial therapy 
 
 
Requirements for new tests 
 Simple high throughput test or “pregnancy style” diffusion test 
 <5 mins 
 Sensitive and specific for Neisseria gonorrhoeae and /or Chlamydia trachomatis 
 Available at the point of care 
 Requires less technical expertise 
 Allows testing using an easily obtainable sample 
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TABLE 3a:  Overview and variables used in economic model for genital 
Chlamydia trachomatis and Neisseria gonorrhoeae 
Variable 
 
 
 
Base case value 
Source/ 
Reference 
Prevalence of   
Chlamydia trachomatis infection 800/100,000        [69] 
Neisseria gonorrhoeae infection 133-196/100,000        [70] 
C trachomatis infection among patients with gonococcal 
infection 
10-40%         [70] 
Sensitivity of test for   
C trachomatis (EIA)            0.70 Table 2 
Specificity of test for   
C trachomatis (EIA)        0.95 Table 2 
Sensitivity of test for   
N gonorrhoeae (EIA)            0.87 Table 2 
Specificity of test for   
N gonorrhoeae (EIA)            0.87 Table 2 
% of Men tested   
C trachomatis            21% [73] 
N Gonorrhoeae            45% Assumed 
Transmission of C trachomatis infection            40% [71] 
Transmission of N gonorrhoeae            50%        [72] 
Transmission of infection to newborn            60%        [71] 
Cost of test for   
C trachomatis (EIA)           2.88 [55] 
N gonorrhoeae (EIA)          similar  
Cost of treatment (drug cost only)against   
C trachomatis (azithromycin)       £8.96        [59] 
C trachomatis (doxycycline)            £2.01        [59] 
N gonorrhoeae (ceftriaxone)            £2.55        [59] 
N gonorrhoeae (cefixime)            £3.78        [59] 
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TABLE 3b:  Overview of frequency and cost of complications for 
undetected genital Chlamydia trachomatis and Neisseria gonorrhoeae 
                               Rates Unit cost (£) [17] 
Chlamydia Gonorrhoeae  
Men    
Epididymitis 2% [17] 1%[69] 142 
Women    
PID 25% [26] 16% [69] 137 
Women with PID    
Ectopic preg 7.6% [17] Similar rates 762 
Infertility 10.8% [17] Similar rates 10,798 
Newborns from PID 
women 
   
Conjunctivitis 14.7% [17] Similar rates 41 
Pneumonia 7% [17] Similar rates 612 
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TABLE 4:  Annual savings which can be made following a move from current 
testing to the new combined test 
 
Number 
Screened 
Testing For PID 
probability 
Combined PoC Test 
Savings 
Min Scenario 
 
1,000,000 
 
Chlamydia 25% £12,924,268 
100,000 
 
Gonorrhoea 16% £948,874 
Total 
 
  £13,873,142 
Max Scenario 
 
5,000,000 
 
Chlamydia 25% £41,806,587 
1,000,000 
 
Gonorrhoea 16% £5,392,744 
Total 
 
  £47,199,331 
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TABLE 5:  Home Testing Kits1 for STIs 
 
Provider 
Tests Cost Service type 
Boots 
 
Chlamydia Test Kit 
 
£24.47 Treatment through NHS or can be 
purchased at Boots 
 
[http://www.boots.com] 
Most Pharmacies Clamelle Chlamydia Test 
Kit  
 
 
 
£24.47 Treatment through NHS or 
participating pharmacies (must be 
purchased as it is not provided for free 
by Clamelle) 
 
[http://www.clamelle.co.uk/] 
 
Lloyds Pharmacy Chlamydia home testing 
kit 
£30.00 Free treatment if positive  
[http://onlinedoctor.lloydspharmacy.c
om/] 
Chlamydia and 
gonorrhoea test -  
 
£47.99  
Free treatment if positive  
Freetestme 
 
Chlamydia test Free Free Chlamydia postal testing to 15 - 
24 years olds. Free treatment is 
positive 
[http://freetest.me.uk/] 
 
STI Clinic 
 
Chlamydia test 
 
£29.95 Free treatment if positive 
[http://www.thesticlinic.com/] 
 
Gonorrhoea test £29.95 Free treatment if positive 
Chlamydia/Gonorrhoea 
Combination test 
£39.95 Free treatment if positive 
Full STI Screen 
Chlamydia, Gonorrhoea, 
Herpes, Mycoplasma 
Genitalium, Ureaplasma 
Urealyticum/Parvum, 
Trichomonas Vaginalis, 
Gardnerella/Bacterial 
Vaginosis 
£139.95 Free treatment if positive 
 
1
  All services are confidential. 
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